My Treatment Approach: Modern Perspectives on the Management of Chronic Phase CML (CP-CML)

EP. 11: Assessing and Achieving Early Clinical Milestones to Improve Potential for TFR

August 8th 2025

Experts emphasize that achieving early and deep molecular responses—such as MMR and MR4.5—is key to identifying patients most likely to reach treatment-free remission, but careful interpretation of molecular fluctuations, patient education, and the development of better biomarkers remain essential for optimizing discontinuation strategies in CML care.

EP. 12: Choosing Between Treatment De-escalation and Full Discontinuation Prior to TFR

August 15th 2025

Panelists note that treatment discontinuation in patients with sustained deep remission typically follows complete cessation after several years, with stepwise dose de-escalation serving as an option for those facing adverse effects or adherence challenges, emphasizing individualized decisions based on patient goals and careful monitoring.

EP. 13: Offering Hope and Academic Collaboration to Patients Being Treated for CP-CML

August 15th 2025

Panelists conclude on an optimistic note, highlighting that advances in therapy and collaborative care have transformed chronic-phase chronic myeloid leukemia (CP-CML) into a highly manageable disease with improved outcomes, treatment-free remission (TFR) possibilities, and a promising future marked by continued progress and patient-centered care.

EP. 14: Frontline CP-CML Treatment Selection: Patient Goals and the Role of Asciminib

September 17th 2025

An expert discusses how patient-specific goals influence frontline treatment decisions in CP-CML, emphasizing the unique efficacy and safety profile of asciminib compared to second-generation TKIs and identifying potential subgroups who may benefit most from its use.

EP. 15: Frontline CP-CML Treatment Selection: Treatment-related Toxicities and the Minimally Effective Dose

September 17th 2025

An expert discusses how managing treatment-related toxicities—especially fatigue, musculoskeletal pain, GI symptoms, and cardiovascular events—is critical in CP-CML, highlighting strategies such as dose adjustments, supportive care, and selecting better-tolerated TKIs like asciminib to improve adherence and patient outcomes.

EP. 16: Frontline CP-CML Treatment Selection: Treatment-free Remission Eligibility and Retreatment After Relapse

September 17th 2025

An expert discusses how treatment-free remission (TFR) in CP-CML is achievable for a carefully selected subset of patients with sustained deep molecular response, emphasizing the importance of individualized decision-making, close molecular monitoring post-discontinuation, and the reassuring ability to regain response upon TKI reinitiation if relapse occurs.